Summary of minutes of EUCAST Steering Committee Meeting
Milan, Italy, 10-11 May 2011

Attending
Dr Petra Apfalter PA EUCAST General Committee Austria
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom
Dr Rafael Canton RC Clinical Data Co-ordinator Spain
Dr Christian Giske CG SRGA Sweden
Dr Marina Ivanova MI EUCAST General Committee Estonia
Prof Gunnar Kahlmeter GK Chairperson Sweden
Prof Alasdair P. MacGowan AM BSAC United Kingdom
Dr Johan W. Mouton JM CRG The Netherlands
Prof Arne Rodloff AR DIN Germany
Prof Claude-James Soussy CS CA-SFM France
Dr Martin Steinbakk MS NWGA Norway
Dr Radu Botgros RB EMA United Kingdom
Dr Mair Powell MP MHRA United Kingdom
Prof Irja Lutsar IL CHMP Estonia

Present for items 23 to 25

1 Chairman’s welcome

2 Minutes of meeting of 15-16 February 2011 The minutes were accepted as a correct record.

3 Matters arising from minutes of 15-16 Feb 2011 (items not covered by agenda)
A paper explaining ECOFFs is in preparation and will be submitted to CMI.

MIC distributions for *C. difficile* have been added to the MIC database.

EMA will be asked for a view on EUCAST setting breakpoints for agent-organism combinations for which there is no marketing approval. Comments on the draft EMA “Guideline on the Evaluation of Medicinal Products indicated for Bacterial Infections” have been sent to EMA.

A draft paper explaining Pk/Pd breakpoints has been prepared.

Gonococcal susceptibility testing methods are being investigated.

A proposal to change cefixime breakpoints for *N. gonorrhoeae* is in progress.

Photographs and notes on testing *S. aureus* for β-lactamase production are being prepared.

4 New agents A new glycopeptide is likely to receive marketing approval in the near future. A new cefalosporin is being assessed. Fidaxomicin has been deferred by EMA. An application for extension of indications for a fluoroquinolone has been withdrawn by the company.

5 Status of EUCAST rationale documents The current status of documents was reviewed.

6 Breakpoint issues Fluoroquinolone breakpoints for viridians streptococci are being discussed.

7 Expert rules subcommittee Version 2 of the rules will soon be on the EUCAST website. The subcommittee will be disbanded.

8 Antifungal susceptibility testing subcommittee Breakpoints and rationale documents for posaconazole, anidulafungin and amphotericin B have been released. Juan Luis Rodriguez-Tudela and Peter Donnelly have resigned from the subcommittee and have been replaced by Maiken Arendrup (Chair) and William Hope (Scientific Secretary).

9 Anaerobe subcommittee Interim results of a study of susceptibility testing methods were reviewed.
10 Organisms without EUCAST breakpoints

11 ESCMID
Proposals for sessions at ECCMID 2012 and for a Postgraduate Educational Course in Madrid in September 2012 will be sent to ESCMID.

It was noted that an ESCMID Mycobacterium study group has been set up.

12 EMA No new information.

13 CLSI No new information.

14 ECDC No new information.

15 Implementation of EUCAST breakpoints
Maps of country status regarding National Antimicrobial Susceptibility Testing Committees, implementation of breakpoints and implementation of the disk diffusion test are being developed.

Validation of gradient tests on MH-F medium remains an issue.

Breakpoints for topical agents are to be discussed.

A questionnaire on national doses of antimicrobial agents will be prepared.

The review of Moraxella catarrhalis breakpoints was completed and breakpoints will be released.

The format for MIC dilution series will be in line with that used by CMI, JAC and ASM journals.

16 EUCAST statutes The revised statutes will be published on the EUCAST website.

17 Website No new information.

18 Co-amoxiclav breakpoints and susceptibility testing Publications or unpublished clinical data correlating outcome with an amoxicillin/clavulanate breakpoint of 8/4 mg/L are not available.

19 Direct antimicrobial susceptibility testing Guidelines will be prepared.

20 Cefoxitin for detecting methicillin resistance in coagulase-negative staphylococci There was good correlation of cefoxitin zone diameters with confirmed mecA status in a recent study.

21 Ciprofloxacin breakpoints for Salmonella spp. The reliability of a ciprofloxacin disk diffusion test for detecting reduced susceptibility is being investigated.

22 Breakpoints splitting the wild type Discrepancies are being investigated.

23-25 New cefalosporin The agent was presented by the company.

26 Any other business None

27 Next meetings
26-27 September 2011, Berlin, Germany (to be confirmed).
21-22 November 2011, Brussels, Belgium
30-31 January 2012, Paris, France
3-4 April 2012, London, UK (after ECCMID)
9-10 July 2012, Stockholm, Sweden
24-25 September 2012, Madrid, Spain

Ratified summary of minutes of meeting 10-11 May 2011. Prepared by DB, GK and RC